NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/06/2026
Voltar para busca
Dado oficial do USPTO
PINOVA THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PINOVA THERAPEUTICS
ST13
US500000097135396Classe
5, 42, 44
Pedido
97135396
Registro
8285284
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
02/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
19/11/2021
Data de registro
02/06/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/06/2026
Última transação
02/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
03/06/2025
Primeiro uso no comércio
03/06/2025
Código do desenho
4
Tipo de titular
03
Localização do titular
Bethesda, MD, US
Examinador
ATTANG, UDEME U
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Pocket Naloxone Corp.
Representantes
Spencer Wolff Esquire Spencer Wolff Law PC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
pharmaceutical preparations for the treatment of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapy side effectssmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty
Classe 42
scientific research and development into treatments of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty; pharmaceutical research and development into treatments of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty; pharmaceutical research and development into treatments of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty; pharmaceutical research and development into treatments of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty
Classe 44
medical and healthcare information services namely providing medical and healthcare information in the fields of opioid dependencebenzodiazepine dependenceanaphalytic shockseizureshypoglycemianeurodegenerative disordersallergiesblood pressureacute chest painmastocytosis diseasepain managementanxietypost-traumatic stress disordersleep disordershypercalcaemiaosteoporosismigraineshormone replacement therapysmoking cessationnauseamotion sicknessheartburnindigestionacid refluxhemophiliac bleedingurinary incontinencemood disordersvitamin deficiencieslow phosphate levelsdiarrheaasthmachronic obstructive pulmonary diseaseendometriosisearly puberty
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
02/06/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/05/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/05/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/04/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
06/04/2026
IUAF
USE AMENDMENT FILED
17/10/2025
EISU
TEAS STATEMENT OF USE RECEIVED
17/10/2025
TPEX
SOU EXTENSION RECEIVED WITH TEAS PETITION
17/10/2025
NREV
NOTICE OF REVIVAL - E-MAILED
17/10/2025
PETG
PETITION TO REVIVE-GRANTED
17/10/2025
PROA
TEAS PETITION TO REVIVE RECEIVED
17/10/2025
MAB6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
13/10/2025
ABN6
ABANDONMENT - NO USE STATEMENT FILED
13/10/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
20/02/2025
EX3G
SOU EXTENSION 3 GRANTED
19/02/2025
EXT3
SOU EXTENSION 3 FILED
19/02/2025
EEXT
SOU TEAS EXTENSION RECEIVED
19/02/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
21/08/2024
EX2G
SOU EXTENSION 2 GRANTED
21/08/2024
EXT2
SOU EXTENSION 2 FILED
21/08/2024
EEXT
SOU TEAS EXTENSION RECEIVED
21/08/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/03/2024
EX1G
SOU EXTENSION 1 GRANTED
02/03/2024
EXT1
SOU EXTENSION 1 FILED
02/03/2024
EEXT
SOU TEAS EXTENSION RECEIVED
02/03/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/09/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
18/07/2023
PUBO
PUBLISHED FOR OPPOSITION
18/07/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/06/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/05/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/05/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/05/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/04/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
14/04/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/04/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/04/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/04/2023
GNRT
NON-FINAL ACTION E-MAILED
11/04/2023
CNRT
NON-FINAL ACTION WRITTEN
11/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/02/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/02/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
31/08/2022
GNRT
NON-FINAL ACTION E-MAILED
31/08/2022
CNRT
NON-FINAL ACTION WRITTEN
31/08/2022
DOCK
ASSIGNED TO EXAMINER
30/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/11/2021
NWAP
NEW APPLICATION ENTERED
23/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PINOVA THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.